A Cost-effective Microdevice Bridges Microfluidic and Conventional in vitro Scratch / Wound-healing Assay for Personalized Therapy Validation

다국어 초록 (Multilingual Abstract)

Enhanced motility in malignant cell is one hallmark of tumor metastasis. The clinical reality is that each of us responds differently to treatment, driving a significant interest in the development of therapies that are “right” to the individual. A biomedical analytical tool with low-cost, sensitive and short assaytime is critical for personalized medicine. Herein, a cost-effective and user-friendly microfluidic device was developed for studying of cell migration. A two-step photolithography procedure was conducted to reveal microchannels and microchambers with different depth. The PDMS/glass slide hydride device was assembled between a polymethyl methacrylate (PMMA) clamp which can adjust the pressure imposed on the device to control the fluid communication between mainchambers, thus identical wound (cell-free space) with clear edge can be easily formed within channel without extra chemical, mechanical force, fluidic manipulation and sophisticated microstructure. Using this device, we evaluated the combinatory of BRAFV600E inhibitor vemurafenib and epidermal growth factor receptor (EGFR) inhibitor gefitinib in inhibiting of melanoma cell migration with only 20 μL cell consumption, highlighting its potential in assaying rare clinical biopsy for personalized medicine. In addition, the on-chip migration model followed strictly follow the principle of conventional in vitro scratch/wound healing assay, facilitating it is translation to biologist.

참고문헌 (Reference)

1 Prahallad, A., "Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR" 483 : 100-103, 2012

2 Zervantonakis, I.K., "Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function" 109 : 13515-13520, 2012

3 Joseph, E.W., "The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner" 107 : 14903-14908, 2010

4 Yu, L., "The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells" 50 : 294-302, 2011

5 Sun, C., "Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma" 508 : 118-122, 2014

6 Kunze, A., "Research highlights: measuring and manipulating cell migration" 14 : 4117-4121, 2014

7 Wu, J., "Recent developments in microfluidics-based chemotaxis studies" 13 : 2484-2499, 2013

8 Ong, F.S., "Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing" 12 : 593-602, 2012

9 Jackson, S.E., "Personalised cancer medicine" 201 (201): 262-266, 2015

10 Jowhar, D., "Open access microfluidic device for the study of cell migration during chemotaxis" 2 : 648-658, 2010

11 Nie, F.Q., "On-chip cell migration assay using microfluidic channels" 28 : 4017-4022, 2007

12 Chaw, K. C., "Multi-step microfluidic device for studying cancer metastasis" 7 : 1041-1047, 2007

13 Boneschansker, L., "Microfluidic platform for the quantitative analysis of leukocyte migration signatures" 5 : 4787-, 2014

14 Jeong, G.S., "Microfluidic assay of endothelial cell migration in 3D interpenetrating polymer semi-network HA-Collagen hydrogel" 13 : 717-723, 2011

15 Nazarian, R., "Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation" 468 : 973-977, 2010

16 Chaw, K. C., "Matrigel coated polydimethylsiloxane based microfluidic devices for studying metastatic and non-metastatic cancer cell invasion and migration. Biomed" 9 : 597-602, 2007

17 Zheng, C., "Live cell imaging analysis of the epigenetic regulation of the human endothelial cell migration at single-cell resolution" 12 : 3063-3072, 2012

18 Shin, M. K., "Integration of intraand extravasation in one cell-based microfluidic chip for the study of cancer metastasis" 11 : 3880-3887, 2011

19 Flaherty, K.T., "Inhibition of mutated, activated BRAF in metastatic melanoma" 363 : 809-819, 2010

20 Girotti, M.R., "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma" 3 : 158-167, 2013

21 Liang, C. C., "In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro" 2 : 329-333, 2007

22 Chapman, P.B., "Improved survival with vemurafenib in melanoma with BRAF V600E mutation" 364 : 2507-2516, 2011

23 Gross, A., "Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway" 10 : 77-84, 2015

24 Djerf, E.A., "ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells:inhibition by gefitinib (ZD1839)" 19 : 156-166, 2009

25 Wang, J., "Epitaxially Grown Collagen Fibrils Reveal Diversity in Contact Guidance Behavior among Cancer Cells" 31 : 307-314, 2015

26 Hou, Y., "Collagen attachment to the substrate controls cell clustering through migration" 11 : 056007-, 2014

27 Lauffenburger, D.A., "Cell migration: a physically integrated molecular process" 84 : 359-369, 1996

28 Eccles, S. A., "Cell migration/invasion assays and their application in cancer drug discovery" 11 : 391-421, 2005

29 Lamberti, G., "Bioinspired microfluidic assay for in vitro modeling of leukocyte-endothelium interactions" 86 : 8344-8351, 2014

30 Riahi, R., "Advances in wound-healing assays for probing collective cell migration" 17 : 59-65, 2012

31 Zhang, M., "A simple microfluidic strategy for cell migration assay in an in vitro wound-healing model" 21 : 897-903, 2013

32 Patel, S.P., "A phase II study of gefitinib in patients with metastatic melanoma" 21 : 357-363, 2011

33 van der Meer, A.D., "A microfluidic wound-healing assay for quantifying endothelial cell migration" 298 : H719-H725, 2010

34 Cheng, S.Y., "A hydrogel-based microfluidic device for the studies of directed cell migration" 7 : 763-769, 2007